Stock Track | Keymed Bio Soars as New Cancer Drug Wins China Approval

Stock Track09-12

Shares of Keymed Biosciences Inc. surged as much as 6.7% on Wednesday after the biotech company announced a major regulatory milestone for one of its leading drug candidates.

The Chinese biopharmaceutical firm said its drug Stapokibart has been granted marketing approval from the National Medical Products Administration (NMPA) in China. Stapokibart is a third-generation EGFR tyrosine kinase inhibitor being developed for the treatment of non-small cell lung cancer.

The NMPA approval marks a significant step forward for Keymed and paves the way for Stapokibart to enter the commercial market in China. Lung cancer is one of the most prevalent forms of cancer in the country, underscoring the large potential patient population for the newly approved therapy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160192213?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-12 18:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160192213","market":"hk","top_or_hot":-1,"title":"Stock Track | Keymed Bio Soars as New Cancer Drug Wins China Approval","media":"Stock Track","content":"<p>Shares of Keymed Biosciences Inc. surged as much as 6.7% on Wednesday after the biotech company announced a major regulatory milestone for one of its leading drug candidates.</p>\n\n<p>The Chinese biopharmaceutical firm said its drug Stapokibart has been granted marketing approval from the National Medical Products Administration (NMPA) in China. Stapokibart is a third-generation EGFR tyrosine kinase inhibitor being developed for the treatment of non-small cell lung cancer.</p>\n\n<p>The NMPA approval marks a significant step forward for Keymed and paves the way for Stapokibart to enter the commercial market in China. Lung cancer is one of the most prevalent forms of cancer in the country, underscoring the large potential patient population for the newly approved therapy.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Keymed Bio Soars as New Cancer Drug Wins China Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Keymed Bio Soars as New Cancer Drug Wins China Approval\n</h2>\n\n<h4 class=\"meta\">\n\n2024-09-12 18:32 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Keymed Biosciences Inc. surged as much as 6.7% on Wednesday after the biotech company announced a major regulatory milestone for one of its leading drug candidates.\nThe Chinese ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1160192213","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160192213","pubTimestamp":1726137134,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Keymed Biosciences Inc. surged as much as 6.7% on Wednesday after the biotech company announced a major regulatory milestone for one of its leading drug candidates.The Chinese biopharmaceutical firm said its drug Stapokibart has been granted marketing approval from the National Medical Products Administration  in China. Stapokibart is a third-generation EGFR tyrosine kinase inhibitor being developed for the treatment of non-small cell lung cancer.The NMPA approval marks a significant s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"癌症新药获得中国批准，股票赛道康盟生物飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"Shares of Keymed Biosciences Inc. surged as much as 6.7% on Wednesday after the biotech company announced a major regulatory milestone for one of its leading drug candidates.\nThe Chinese biopharmaceutical firm said its drug Stapokibart has been granted marketing approval from the National Medical Products Administration (NMPA) in China. Stapokibart is a third-generation EGFR tyrosine kinase inhibitor being developed for the treatment of non-small cell lung cancer.\nThe NMPA approval marks a significant step forward for Keymed and paves the way for Stapokibart to enter the commercial market in China. Lung cancer is one of the most prevalent forms of cancer in the country, underscoring the large potential patient population for the newly approved therapy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160192213"}